Azərbaycanca
Deutsch
English
Français
Русский
ภาษาไทย
Українська
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
The European and Developing Countries Clinical Trials Partnership (EDCTP) is a partnership between the European Union (EU), Norway, Switzerland and developing countries and other donors, as well as the pharmaceutical industry, to enable clinical trials and the development of new medicines and vaccines against HIV/AIDS, tuberculosis, and malaria.[2] The need for global action against these diseases in order to promote poverty reduction has been recognised by the United Nations, the G8, and the African Union, and the program envisioned the provision of €600 million for the period 2003–2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries.
The European Council adopted the Programme for Action: Accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction (COM (2001)96, [3]) on 15 May 2001, following its launch by the European Commission. The Commission proposal was adopted on 16 June 2003 by the Council and the European Parliament.[4][permanent dead link] The Programme was to be based on three central pillars: "the impact of existing interventions, the affordability of key pharmaceuticals and trade, and the research and development of specific global public goods."[5] These aims relate specifically with the EU stance on access to essential medicines. [6]
Projects and activities
EDCTP-funded activities are based on:
- North/North networking and co-ordination
Partnerships among the EU and associated countries, allowing focused collaboration of national and European efforts that were not previously coordinated.
- North/South networking and co-ordination
Partnerships among EU and developing countries that focuses specifically on developing countries' needs, who are jointly involved in setting the research priorities.
- South/South networking and co-ordination
Efforts aimed at creating lasting long-term partnerships between African scientists and research institutions in Africa.
- Supporting relevant clinical trials
Acceleration of the development of new or improved drugs, vaccines and microbicides against HIV/AIDS, malaria and tuberculosis, with a focus on phase II and III clinical trials in sub-Saharan Africa.
- Capacity building
Manifested as a general strengthening of clinical research capacity in Africa, including training activities, workshops and meetings, and the upgrading of clinical trial sites in Africa.
Funding
The total budget of the EDCTP is €600 million for the period 2003–2007, of which one third (€200 million) is to be provided by the EU budget, an equivalent amounts from Member States' activities, and the remaining €200 million from industry, charities, and private organisations. The Partnership is intended to be a long-term initiative (10–20 years) and a separate legal entity has been created to maintain its independence and flexibility.[citation needed]
Taken together, clinical trials based in developing countries where the diseases are endemic, capacity building, and South-South networking are expected to make up over 90% of the overall budget. (figure).
Member states and partners
Are as follows:
- Europe
- EU member states, plus Norway and Switzerland .
- Developing countries
- All sub-Saharan African countries.
- Industry and commercial
- Bayer
- GlaxoSmithKline
- Novo Nordisk
- Sanofi Pasteur
- Sanofi-Aventis.
- International initiatives
- The World Health Organization (WHO-TDR) ()
- Drugs for Neglected Diseases initiative (http://www.dndi.org)
- International Aids Vaccine Initiative (IAVI) (http://www.iavi.org)
- European Vaccine Initiative (EVI) (http://www.euvaccine.eu)
- TB Alliance (http://www.tballiance.org)
- Private non-profit organisations
- ()
- The Bill and Melinda Gates Foundation ()
- International Partnership for Microbicides ()
- Medicines for Malaria Venture ()
- The Wellcome Trust (http://www.wellcome.ac.uk)
See also
- European Organisation for Research and Treatment of Cancer (EORTC)
- European Medicines Agency (EMEA)
References
- "Research and innovation - European Commission" (PDF).
External links
- European and Developing Countries Clinical Trials Partnership (EDCTP)
Author: www.NiNa.Az
Publication date:
wikipedia, wiki, book, books, library, article, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games, mobile, phone, android, ios, apple, mobile phone, samsung, iphone, xiomi, xiaomi, redmi, honor, oppo, nokia, sonya, mi, pc, web, computer
This article has multiple issues Please help improve it or discuss these issues on the talk page Learn how and when to remove these messages This article may rely excessively on sources too closely associated with the subject potentially preventing the article from being verifiable and neutral Please help improve it by replacing them with more appropriate citations to reliable independent sources February 2013 Learn how and when to remove this message This article includes a list of general references but it lacks sufficient corresponding inline citations Please help to improve this article by introducing more precise citations February 2021 Learn how and when to remove this message This article needs to be updated Please help update this article to reflect recent events or newly available information April 2021 Learn how and when to remove this message The European and Developing Countries Clinical Trials Partnership EDCTP is a partnership between the European Union EU Norway Switzerland and developing countries and other donors as well as the pharmaceutical industry to enable clinical trials and the development of new medicines and vaccines against HIV AIDS tuberculosis and malaria 2 The need for global action against these diseases in order to promote poverty reduction has been recognised by the United Nations the G8 and the African Union and the program envisioned the provision of 600 million for the period 2003 2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries The European Council adopted the Programme for Action Accelerated action on HIV AIDS malaria and tuberculosis in the context of poverty reduction COM 2001 96 3 on 15 May 2001 following its launch by the European Commission The Commission proposal was adopted on 16 June 2003 by the Council and the European Parliament 4 permanent dead link The Programme was to be based on three central pillars the impact of existing interventions the affordability of key pharmaceuticals and trade and the research and development of specific global public goods 5 These aims relate specifically with the EU stance on access to essential medicines 6 Projects and activitiesEDCTP funded activities are based on North North networking and co ordination Partnerships among the EU and associated countries allowing focused collaboration of national and European efforts that were not previously coordinated North South networking and co ordination Partnerships among EU and developing countries that focuses specifically on developing countries needs who are jointly involved in setting the research priorities South South networking and co ordination Efforts aimed at creating lasting long term partnerships between African scientists and research institutions in Africa Supporting relevant clinical trials Acceleration of the development of new or improved drugs vaccines and microbicides against HIV AIDS malaria and tuberculosis with a focus on phase II and III clinical trials in sub Saharan Africa Capacity building Manifested as a general strengthening of clinical research capacity in Africa including training activities workshops and meetings and the upgrading of clinical trial sites in Africa FundingProposed EDCTP expenditure for the first five years of the Programme 2003 2007 1 The total budget of the EDCTP is 600 million for the period 2003 2007 of which one third 200 million is to be provided by the EU budget an equivalent amounts from Member States activities and the remaining 200 million from industry charities and private organisations The Partnership is intended to be a long term initiative 10 20 years and a separate legal entity has been created to maintain its independence and flexibility citation needed Taken together clinical trials based in developing countries where the diseases are endemic capacity building and South South networking are expected to make up over 90 of the overall budget figure Member states and partnersAre as follows Europe EU member states plus Norway and Switzerland Developing countries All sub Saharan African countries Industry and commercial Bayer GlaxoSmithKline Novo Nordisk Sanofi Pasteur Sanofi Aventis International initiatives The World Health Organization WHO TDR Drugs for Neglected Diseases initiative http www dndi org International Aids Vaccine Initiative IAVI http www iavi org European Vaccine Initiative EVI http www euvaccine eu TB Alliance http www tballiance org Private non profit organisations The Bill and Melinda Gates Foundation International Partnership for Microbicides Medicines for Malaria Venture The Wellcome Trust http www wellcome ac uk See alsoEuropean Organisation for Research and Treatment of Cancer EORTC European Medicines Agency EMEA References Research and innovation European Commission PDF External linksEuropean and Developing Countries Clinical Trials Partnership EDCTP